A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER To determine the antitumor efficacy of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks repeated every 6 weeks in patients having metastatic NSCLC who have previously...

• Country None
• organs None
• Specialty None

One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera®) on Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents. Ensayo abierto de un año y de grupos paralelos para evaluar el impacto de la disponibilidad de insulina a inhalada (Exubera) sobre el control glucémico de pacientes ambulatorios orales To demonstrate that mean reduction in HbA1c after 52 weeks (approx. 12 months) is greater in patients to whom inhaled insulin is made available compared to patients to whom it is not.

• Country None
• organs None
• Specialty None

A multicenter, double-blind placebo controlled, fixed dose study with an open-label, flexible dose phase to assess the efficacy of Sildenafil Citrate in providing a better sexual experience including quality of erections and satisfaction in men with erectile dysfunction To evaluate the effect of sildenafil citrate versus placebo on the IIEF-EF Domain at the end of the double-blind phase.

• Country None
• organs None
• Specialty None

ESTUDIO EN FASE 2, DE UN SOLO GRUPO, DE CP 751,871 EN PACIENTES CON ADENOCARCINOMA DE COLON O RECTO METASTÁSICO REFRACTARIO A PHASE II, SINGLE ARM STUDY OF CP-751,871 IN PATIENTS WITH REFRACTORY METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM Evaluar la supervivencia global a los seis meses en pacientes con cáncer colorrectal metastásico refractario que reciben CP-751,871.

• Country None
• organs None
• Specialty None

A RANDOMIZED PHASE 2 STUDY OF SU011248 VERSUS STANDARD-OF-CARE FOR PATIENTS WITH PREVIOUSLY TREATED, ADVANCED, TRIPLE RECEPTOR NEGATIVE (ER, PR, AND HER2) BREAST CANCER Estudio aleatorizado en Fase 2 de SU011248 frente al tratamiento estándar en pacientes con cáncer de mama avanzado, tratados previamente y con triple receptor negativo (ER, PR y HER2) To compare the progression-free survival for SU011248 versus standard-of-care therapy in patients with previously treated, triple receptor negative (ER/PR and HER2/neu), locally recurrent or metastati...

• Country None
• organs None
• Specialty None

Estudio en fase 2 aleatorizado de cisplatino/pemetrexed con o sin axitinib (AG-013736) para el tratamiento en primera línea de pacientes con cáncer de pulmón no microcítico no escamoso ? Evaluar la eficacia de axitinib administrado continuamente en combinación con pemetrexed /cisplatino comparado con pemetrexed /cisplatino solos en pacientes con CPNM no escamoso. ? Evaluar la eficac...

• Country None
• organs None
• Specialty None

An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV Generalized Anxiety Disorder in outpatients To evaluate the efficacy of Pregabalin and Venlafaxine XR (extended release) compared to placebo in the treatment of GAD).

• Country None
• organs None
• Specialty None

A 102-Week, open label, multicenter trial to investigate the efficacy of macugen for the preservation of visual function in subjects with neovascular age-related macular degeneration (AMD) and to assess the benefit of treating early choroidal neovascularization (CNV) To assess the efficacy of Macugen 0.3 mg for the preservation of vision in subjects with early CNV lesions and established CNV lesions.

• Country None
• organs None
• Specialty None

A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma To compare the time to tumor progression (TTP) associated with SU011248 versus that associated with IFN-a for the first-line treatment of patients with metastatic renal cell carcinoma

• Country None
• organs None
• Specialty None

A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOL Protocolo de continuación de tratamiento para pacientes provenientes de un protocolo previo con SU011248 The primary objective is to provide access to SU011248 treatment for patients who have partecipated in other SU011248 protocol and have the potentila to derive clincial benefit from SU011248 tretamen...

• Country None
• organs None
• Specialty None